Kennedy Capital Management’s Abivax ABVX Stock Holding History

Kennedy Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Buy	19,200 +10,443	+119%	+$1.18M	0.05%	418
2026 Q1	$975K	Buy	+8,757	New	+$1.04M	0.02%	489
2025 Q3	–	Sell	-241,188	Closed	-$1.85M	–	556
2025 Q2	$1.85M	Buy	241,188 +15,997	+7%	+$104K	0.04%	450
2025 Q1	$1.41M	Sell	225,191 -279	-0.1%	-$1.89K	0.03%	473
2024 Q4	$1.65M	Buy	225,470 +1,656	+0.7%	+$15.2K	0.04%	542
2024 Q3	$2.58M	Buy	223,814 +91,783	+70%	+$1.1M	0.06%	467
2024 Q2	$1.75M	Buy	132,031 +11,863	+10%	+$170K	0.04%	528
2024 Q1	$1.72M	Buy	120,168 +31,331	+35%	+$404K	0.04%	548
2023 Q4	$951K	Buy	+88,837	New	+$905K	0.02%	592

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kennedy Capital Management's ABVX Position: Q2 2026 in Review

Kennedy Capital Management increased its Abivax (ABVX) stake by 119% in Q2 2026, buying an estimated $1.18M and bringing the position to 19,200 shares worth $2.56M. The position accounts for 0.05% of the portfolio, ranked #418.

Kennedy Capital Management first reported a position in ABVX in Q4 2023 and has held it in 9 quarters since. The position peaked at $2.58M in Q3 2024. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Kennedy Capital Management held 19,200 shares of Abivax worth $2.56M as of Q2 2026.
Kennedy Capital Management bought 10,443 Abivax shares in Q2 2026, an estimated $1.18M.
Abivax made up 0.05% of Kennedy Capital Management's portfolio in Q2 2026, its #418 holding.
Kennedy Capital Management first reported a position in Abivax in Q4 2023 and has held it in 9 quarters since.
Kennedy Capital Management's Abivax position peaked at $2.58M in Q3 2024.
302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.